KRAS and neoplasm: The generally high awareness observed in the physician survey is also confirmed to an extent by Round 3 of the MRR, which provided insight into how this knowledge is being applied in routine clinical practice, and showed that the majority of patients are being tested for RAS tumour status before treatment initiation, but highlighted the fact that some patients are still only being tested for KRAS mutation status.